ABEO Abeona Therapeutics Inc
Price (delayed)
$5.86
Market cap
$254.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.24
Enterprise value
$261.79M
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
Highlights
Abeona Therapeutics's equity has surged by 108% YoY but it has decreased by 38% QoQ
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of ABEO
Market
Valuations
Earnings
Shares outstanding
43.47M
Market cap
$254.74M
Enterprise value
$261.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$60.75M
Net income
-$71.03M
EBIT
-$67.8M
EBITDA
-$64.95M
Free cash flow
-$50.53M
Per share
Balance sheet
Liquidity
EPS
-$2.24
EPS diluted
-$2.69
Free cash flow per share
-$1.05
Book value per share
$1.06
Revenue per share
$0
TBVPS
$2.51
Total assets
$120.59M
Total liabilities
$74.82M
Debt
$23.11M
Equity
$45.77M
Working capital
$94.24M
Debt to equity
0.5
Current ratio
6.12
Quick ratio
6.06
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-72.2%
Return on equity
-227.4%
Return on invested capital
-83.7%
Return on capital employed
-66.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABEO stock price
How has the Abeona Therapeutics stock price performed over time
Intraday
6.55%
1 week
8.32%
1 month
-2.66%
1 year
32.58%
YTD
5.21%
QTD
5.21%
Financial performance
How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.75M
Net income
-$71.03M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
Abeona Therapeutics's net income has shrunk by 59% YoY and by 35% QoQ
The operating income has decreased by 35% YoY and by 7% from the previous quarter
Growth
What is Abeona Therapeutics's growth rate over time
Valuation
What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
5.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ABEO's EPS has dropped by 58% year-on-year and by 7% since the previous quarter
Abeona Therapeutics's equity has surged by 108% YoY but it has decreased by 38% QoQ
The price to book (P/B) is 98% higher than the 5-year quarterly average of 2.8
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Abeona Therapeutics business performance
The company's return on assets fell by 16% QoQ but it rose by 4.2% YoY
The company's return on invested capital fell by 14% QoQ but it rose by 6% YoY
Abeona Therapeutics's return on equity has decreased by 9% QoQ but it has increased by 2.3% YoY
Dividends
What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABEO.
Financial health
How did Abeona Therapeutics financials performed over time
The company's total assets is 61% higher than its total liabilities
The company's total assets has surged by 82% YoY but it fell by 10% QoQ
ABEO's total liabilities has soared by 70% YoY and by 23% QoQ
Abeona Therapeutics's debt is 50% lower than its equity
Abeona Therapeutics's equity has surged by 108% YoY but it has decreased by 38% QoQ
Abeona Therapeutics's debt to equity has surged by 92% YoY and by 56% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.